12/7/22 CC Cyrus “18:50: Within oncology,
Post# of 155592
Cyrus
“18:50: Within oncology, we want to pursue colorectal cancer and breast cancer specifically.
Within the colorectal cancer population, we want to focus on a micro-satellite stable group, which represents about 85% of all diagnosed colorectal cancers. And within breast cancer, we want to focus on the hormone receptor positive HER2-negative population, which is about 70% of all diagnosed breast cancers, and the TNBC population since we have data in that space.”
The “urgent data” in CD07. Wonder what it will show us.


CytoDyn Inc (CYDY) Stock Research Links
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com